Atorvastatin to help prevent cisplatin-related hearing loss
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat clinical trials.
This Phase 2 trial tests whether a cholesterol medicine called atorvastatin can protect hearing in people with head and neck cancer receiving cisplatin plus radiation. If it works, it may reduce the chance or severity of treatment-related hearing damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and you can sign consent and follow the study plan for the full study duration
- You have head and neck squamous cell carcinoma confirmed by biopsy or surgery, and you will get cisplatin with radiation (curative) or before surgery (neoadjuvant)
- Your baseline hearing test must be at or better than 70 decibels in at least one ear at 1, 2, and 4 kHz
- You are not already on a statin (cholesterol medicine), and you have no both-ears flat tympanogram and no both-ears cochlear implants
- Your blood and organ tests must be fairly normal (AST/ALT, creatine phosphokinase, and kidney function all under 1.5 times the upper limit)
- You can take the study medicine by mouth or feeding tube daily, and you must use strong birth control (if applicable) during the study and for 8 more weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how radiotherapy, and possibly cisplatin chemotherapy, affect hearing in people treated for head and neck cancer. It may help doctors better predict hearing side effects and plan hearing monitoring or prevention.
This study looks at how cisplatin chemotherapy affects hearing and balance in people with head and neck cancer. It compares those getting cisplatin-based treatment to those getting only radiation. The goal is to better understand and potentially reduce these side effects.
This trial tests whether a medicine called sodium thiosulfate can protect your hearing from the side effects of cisplatin chemotherapy. It is for people with newly diagnosed cancer who are about to receive cisplatin for the first time.
This trial tests whether adding Pedmark (sodium thiosulfate) to cisplatin chemotherapy can protect hearing in men with stage II or III testicular germ cell tumors. It aims to reduce the risk of drug-related ear damage while still treating the cancer.
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Hear when a new Hearing Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.